Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
KARD · against 1,336 other Healthcare companies
Ranked #1,249 of 1,337 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score385 peers with a valuation score of 0–9, including KARD · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | KARD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -21.6% | 1.5% | 11% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | -35.2% | 4.2% | 7% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | Not reported | -1.0% | — | — | 20% |
| Book yieldHigher is better · 1,306 reported | 46.0% | 37.9% | 59% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1,249 | 1.2B CHF (≈$1.3B) | 0 | 28 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 1,249 | 18M AUD (≈$12M) | 0 | 7 |
| 1,249 | 952M USD | 0 | 3 |
| 1,249 | 1.4B USD | 0 |
| 1,249 | 1.3B USD | 0 |
| 1,249 | 1.6B USD | 0 |
| 1,249 | 1.0B EUR (≈$1.1B) | 0 | 16 |
| 1,249 | 332M USD | 0 | 35 |
| 1,249 | 1.0B USD | 0 | 32 |